Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936544 | 0.95 | SCD (0.88) | SCDDCTPP1 | |
| SCHEMBL1377949 | 0.94 | SCD (1.00) | SCDDCTPP1 | |
| SCHEMBL937531 | 0.89 | SCD (1.00) | SCDDCTPP1 | |
| SCHEMBL1376607 | 0.88 | SCD (0.86) | SCDDCTPP1 | |
| SCHEMBL1600619 | 0.87 | SCD (0.68) | SCDDCTPP1 | |
| SCHEMBL1377165 | 0.87 | SCD (0.90) | SCDDCTPP1 | |
| SCHEMBL938244 | 0.87 | SCD (0.87) | SCDDCTPP1 | |
| SCHEMBL938774 | 0.87 | SCD (0.67) | SCDDCTPP1 | |
| SCHEMBL1376810 | 0.86 | SCD (1.00) | SCDDCTPP1 | |
| SCHEMBL2470074 | 0.86 | SCD (0.66) | SCDDCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4808616-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | disclosed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | disclosed |
| US-7964591-B2 | Pyridazine derivatives and their use as therapeutic agents | NOVARTIS PHARMA AG (CH) | 2011-06-21 | — | — | US | disclosed |
| EP-2316827-A1 | Piperazine derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| US-7919484-B2 | Combination therapy | XENON PHARMACEUTICALS INC. (CA) | 2011-04-05 | — | — | US | disclosed |
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | PRXL2A, CUTA, MC1R | SCD 52/4885DCTPP1 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.